Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Valproate-induced hyperammonemic encephalopathy.

Alberto Verrotti1, Daniela Trotta, Guido Morgese

  • 1Department of Pediatrics, University of Chieti, Italy.

Metabolic Brain Disease
|February 27, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of the efficacy of two different desmopressin formulations in pediatric patients with nocturnal enuresis: a retrospective observational study.

Central European journal of urology·2026
Same author

Pycnodysostosis: Report of Two Novel CTSK Variants in a Child.

Clinics and practice·2026
Same author

Effects of White Noise on Academic Skills in Children with ADHD and Specific Learning Disorders: New Perspectives for Personalised Rehabilitation and Educational Intervention.

Pediatric reports·2026
Same author

Childhood absence epilepsy and developmental coordination disorder: an intriguing comorbidity.

Seizure·2026
Same author

Soticlestat for drug-resistant epilepsy: Current evidence and clinical perspectives.

Seizure·2026
Same author

A tiered decisional framework for genetic epileptic syndromes with or without encephalopathies: from standard care to investigational strategies.

Expert review of clinical pharmacology·2026

Valproic acid (VPA) can cause hyperammonemic encephalopathy (VHE), a serious neurological side effect. This condition involves impaired consciousness and seizures, potentially linked to astrocyte dysfunction and ammonia accumulation.

Area of Science:

  • Neurology
  • Biochemistry
  • Pharmacology

Background:

  • Valproic acid (VPA) is a widely used anticonvulsant for epilepsy.
  • VPA is associated with neurological and systemic side effects, including VPA-induced hyperammonemic encephalopathy (VHE).
  • VHE presents with acute impaired consciousness, focal neurological signs, and increased seizure frequency.

Purpose of the Study:

  • To explore the pathogenesis of VPA-induced hyperammonemic encephalopathy.
  • To understand the role of astrocytes and ammonia in VHE development.
  • To identify patient factors that may increase VHE risk.

Main Methods:

  • Review of existing literature on VPA side effects and hyperammonemia.
  • Analysis of proposed mechanisms involving astrocyte glutamate uptake and ammonia metabolism.

Related Experiment Videos

  • Examination of patient populations with VHE, including those with carnitine deficiency or urea cycle defects.

    • Main Results:

    • Hyperammonemia in VHE may inhibit astrocyte glutamate uptake, leading to neuronal injury.
    • Elevated intracellular glutamine in astrocytes increases osmolarity, causing swelling and potential cerebral edema.
    • VHE occurrence is higher in patients with carnitine deficiency or urea cycle enzymatic defects.

    Conclusions:

    • VHE pathogenesis likely involves ammonia-induced astrocyte dysfunction and subsequent cerebral edema.
    • Carnitine deficiency and urea cycle defects are risk factors for VHE.
    • Understanding these mechanisms is crucial for managing VPA therapy and preventing VHE.